Human leucocyte antigen-A2 increases risk of Alzheimer's disease but does not affect age of onset in a Scottish population.
The use of non-steroidal anti-inflammatory drugs has been associated with a reduced incidence of Alzheimer's disease (AD), suggesting that attenuation of the inflammatory response may be beneficial. Several, but not all, genetic association studies have shown human leucocyte antigen (HLA)-A2, a major histocompatibility complex class I antigen-binding transmembrane protein has an increased frequency in AD compared to controls, and in some reports is associated with a lowered age of onset. We further investigated the role of HLA-A2 in an independent sample of AD cases, including a large early onset cohort. The results of this current study and meta analysis of all studies available to date support previous evidence of an excess of HLA-A2 in AD, but found no evidence of a relationship with age of onset.
Harris
J M
JM
Department of Psychiatry, University of Birmingham, QE Psychiatric Hospital, B15 2QZ, Birmingham, UK.
Cumming
A M
AM
Craddock
N
N
St Clair
D
D
Lendon
C L
CL
D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D000483:Alleles; D000544:Alzheimer Disease / Q000453:epidemiology* / Q000235:genetics*; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D005787:Gene Frequency; D015789:HLA-A2 Antigen / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D018570:Risk Assessment; D012606:Scotland / Q000453:epidemiology; D017678:Sex Distribution
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D015789:HLA-A2 Antigen